miRagen Therapeutics (MGEN) Tops Q3 EPS by 12c

miRagen Therapeutics (NASDAQ: MGEN) reported Q3 EPS of ($0.27), $0.12 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million, versus $900 thousand reported last year.

For earnings history and earnings-related data on miRagen Therapeutics (MGEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c